HUP9901303A2 - Gyógyszerkészítmény autoimmun betegségek kezelésére - Google Patents

Gyógyszerkészítmény autoimmun betegségek kezelésére

Info

Publication number
HUP9901303A2
HUP9901303A2 HU9901303A HUP9901303A HUP9901303A2 HU P9901303 A2 HUP9901303 A2 HU P9901303A2 HU 9901303 A HU9901303 A HU 9901303A HU P9901303 A HUP9901303 A HU P9901303A HU P9901303 A2 HUP9901303 A2 HU P9901303A2
Authority
HU
Hungary
Prior art keywords
treatment
pharmaceutical composition
autoimmune diseases
pharmaceutical
bindarite
Prior art date
Application number
HU9901303A
Other languages
English (en)
Inventor
Paolo Dionisio
Angelo Guglielmotti
Original Assignee
Angelini Ricerche S.P.A. Societa`Consortile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11372453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9901303(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angelini Ricerche S.P.A. Societa`Consortile filed Critical Angelini Ricerche S.P.A. Societa`Consortile
Publication of HUP9901303A2 publication Critical patent/HUP9901303A2/hu
Publication of HUP9901303A3 publication Critical patent/HUP9901303A3/hu
Publication of HU228051B1 publication Critical patent/HU228051B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány 2-[(1-benzil-3-indazőlil)-metőxi]-2-metil-prőpiőnsavat(bindarit), imműnszűppresszív hatóanyagőt és gyógyászatilagelfőgadható vivőanyagőt tartalmazó gyógyszerkészítményre vőnatkőzik. ŕ
HU9901303A 1995-10-31 1996-10-26 A pharmaceutical composition for the treatment of autoimmune diseases HU228051B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI002242A IT1276031B1 (it) 1995-10-31 1995-10-31 Composizione farmaceutica per il trattamento delle malattie autoimmuni
PCT/EP1996/004672 WO1997016185A2 (en) 1995-10-31 1996-10-26 A pharmaceutical composition for the treatment of autoimmune diseases

Publications (3)

Publication Number Publication Date
HUP9901303A2 true HUP9901303A2 (hu) 1999-09-28
HUP9901303A3 HUP9901303A3 (en) 2001-04-28
HU228051B1 HU228051B1 (en) 2012-09-28

Family

ID=11372453

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901303A HU228051B1 (en) 1995-10-31 1996-10-26 A pharmaceutical composition for the treatment of autoimmune diseases

Country Status (27)

Country Link
US (1) US6020356A (hu)
EP (1) EP0858337B1 (hu)
JP (1) JP4007615B2 (hu)
KR (1) KR19990067237A (hu)
CN (1) CN1229113C (hu)
AT (1) ATE326965T1 (hu)
AU (1) AU721841B2 (hu)
BR (1) BR9611320B1 (hu)
CA (1) CA2236256C (hu)
CZ (1) CZ292258B6 (hu)
DE (1) DE69636167T2 (hu)
DK (1) DK0858337T3 (hu)
EA (1) EA000826B1 (hu)
ES (1) ES2264144T3 (hu)
HK (1) HK1018219A1 (hu)
HU (1) HU228051B1 (hu)
IL (1) IL124291A (hu)
IT (1) IT1276031B1 (hu)
MX (1) MX9803478A (hu)
NO (1) NO324130B1 (hu)
NZ (1) NZ321580A (hu)
PL (1) PL186377B1 (hu)
PT (1) PT858337E (hu)
SK (1) SK284069B6 (hu)
TR (1) TR199800765T2 (hu)
WO (1) WO1997016185A2 (hu)
ZA (1) ZA969060B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ES2335008T3 (es) * 2003-04-24 2010-03-18 Jagotec Ag Comprimido con nucleo coloreado.
ES2400446T5 (es) 2006-08-03 2017-03-13 Horizon Pharma Ag Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
BR112012002130A2 (pt) 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
AU2013255050B2 (en) * 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04506066A (ja) * 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
AU7376494A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
EP0827404A1 (en) * 1995-05-10 1998-03-11 Pfizer Inc. Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
ITMI952242A0 (hu) 1995-10-31
BR9611320B1 (pt) 2010-08-10
US6020356A (en) 2000-02-01
DK0858337T3 (da) 2006-09-18
JP4007615B2 (ja) 2007-11-14
NO981951D0 (no) 1998-04-29
CA2236256C (en) 2005-02-22
EA000826B1 (ru) 2000-04-24
ITMI952242A1 (it) 1997-05-01
EA199800417A1 (ru) 1998-10-29
NO981951L (no) 1998-06-29
HK1018219A1 (en) 1999-12-17
PL186377B1 (pl) 2003-12-31
PT858337E (pt) 2006-09-29
WO1997016185A2 (en) 1997-05-09
AU721841B2 (en) 2000-07-13
CZ132698A3 (cs) 1998-10-14
HUP9901303A3 (en) 2001-04-28
DE69636167T2 (de) 2007-03-29
NO324130B1 (no) 2007-09-03
KR19990067237A (ko) 1999-08-16
CZ292258B6 (cs) 2003-08-13
SK284069B6 (sk) 2004-09-08
CN1229113C (zh) 2005-11-30
CN1207042A (zh) 1999-02-03
EP0858337A2 (en) 1998-08-19
ATE326965T1 (de) 2006-06-15
ES2264144T3 (es) 2006-12-16
AU7493896A (en) 1997-05-22
ZA969060B (en) 1997-05-29
JPH11515020A (ja) 1999-12-21
MX9803478A (es) 1998-11-30
PL326371A1 (en) 1998-09-14
CA2236256A1 (en) 1997-05-09
NZ321580A (en) 2000-02-28
WO1997016185A3 (en) 1997-07-03
EP0858337B1 (en) 2006-05-24
SK57998A3 (en) 1998-12-02
DE69636167D1 (de) 2006-06-29
TR199800765T2 (xx) 1998-08-21
IT1276031B1 (it) 1997-10-24
IL124291A (en) 2001-06-14
HU228051B1 (en) 2012-09-28
BR9611320A (pt) 1999-03-02

Similar Documents

Publication Publication Date Title
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
SE9701398D0 (sv) Novel compounds
NZ262679A (en) Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
AU1227899A (en) Osmotic medicament releasing system
ES2145913T3 (es) Inhibidores de metaloproteasas.
UA29450C2 (uk) Похідні гідроксамової кислоти, спосіб їх одержання, спосіб впливу на хвороби та фармацевтична або ветеринарна композиція, що їх містить
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
CA2229282A1 (en) Use of hyaluronic acid as an immunosuppressant
UA35604C2 (uk) Фармацевтична композиція з антидепресивною активністю
EP0382066A3 (de) Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
ID21682A (id) Turunan-turunan pirolo [3,4-d] pirimidinon dan penggunaannya sebagai obat-obatan
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
HUP0104647A2 (hu) Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
NO894616L (no) Fremgangsmaate for fremstilling av anti-aterosklerotisk aktive diarylforbindelser.
HUP0102380A2 (hu) Terápiás készítmény hiperkalcémiás krízis kezelésére
FI956050A0 (fi) Biologisesti aktiiviset vasopressiinianalogit
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
AU5162196A (en) Novel peptides and remedy for bone diseases containing the same as active ingredient
FR2427822A1 (fr) Medicament pour le traitement des maladies circulatoires, a base de 5-methyl-7-dimethylamino-s-triazolo (1,5-a) pyrimidine
AU2506188A (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance